
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
Both drugs address an unmet need for patients with hemophilia A or B.
Patients with hemophilia and sickle cell both have unmet treatment needs, according toSandra Cuellar, a clinical associate professor and clinical oncology pharmacist at UI Health/University of Illinois at Chicago College of Pharmacy. During her Hematology/Oncology Pipeline Update presentation at the 2022 American Society of Health-System Pharmacists Summer Meetings and Exhibition,1 Cuellar dove into the drugs being researched for these conditions.
Check out our
Reference






